Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Biochemistry
2009 May 19;4819:4063-73. doi: 10.1021/bi802259a.
Show Gene links
Show Anatomy links
Conantokin-Br from Conus brettinghami and selectivity determinants for the NR2D subunit of the NMDA receptor.
Twede VD
,
Teichert RW
,
Walker CS
,
Gruszczyński P
,
Kaźmierkiewicz R
,
Bulaj G
,
Olivera BM
.
???displayArticle.abstract???
Conantokins are venom peptides from marine cone snails that are NMDA receptor antagonists. Here, we report the characterization of a 24 AA conantokin from Conus brettinghami Coomans , H. E. , Moolenbeek , R. G. and Wils , E. ( 1982 ) Basteria 46 ( 1/4 ), 3 - 67 , conantokin-Br (con-Br), the first conantokin that does not have the conserved glutamate residue at position 2. Molecular modeling studies suggest that con-Br has a helical structure between residues 2-13. In contrast to other characterized conantokins, con-Br has a high potency for NMDA receptors with NR2D subunits. To identify determinants for NR2D potency, we synthesized chimeras of con-Br and conantokin-R (con-R); the latter has a approximately 30-fold lower potency for the NR2D subtype. The characterization of two reciprocal chimeras (con-Br/R and con-R/Br), comprising the first 9-10 N-terminal AAs of each conantokin followed by the corresponding C-terminal AAs of the other conantokin demonstrates that determinants for NR2D selectivity are at the N-terminal region. Additional analogues comprising 1-3 amino acid substitutions from each peptide into the homologous region of the other led to the identification of a key determinant; a Tyr residue in position 5 increases potency for NR2D, while Val at this locus causes a decrease. The systematic definition of key determinants in the conantokin peptides for NMDA receptor subtype selectivity is an essential component in the development of conantokin peptides that are highly selective for each specific NMDA receptor subtype.
Bisaga,
Therapeutic potential of NMDA receptor antagonists in the treatment of alcohol and substance use disorders.
2000, Pubmed
Bisaga,
Therapeutic potential of NMDA receptor antagonists in the treatment of alcohol and substance use disorders.
2000,
Pubmed
Bisaga,
In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists.
2000,
Pubmed
Blandl,
Structure-function relationships of the NMDA receptor antagonist peptide, conantokin-R.
2000,
Pubmed
Blandl,
Sequence requirements for the N-methyl-D-aspartate receptor antagonist activity of conantokin-R.
2001,
Pubmed
Case,
The Amber biomolecular simulation programs.
2005,
Pubmed
Cavara,
Shuffling the deck anew: how NR3 tweaks NMDA receptor function.
2008,
Pubmed
Chen,
Conformational changes in conantokin-G induced upon binding of calcium and magnesium as revealed by NMR structural analysis.
1998,
Pubmed
Childers,
N-methyl-D-aspartate antagonists and neuropathic pain: the search for relief.
2007,
Pubmed
Counihan,
Expression of N-methyl-D-aspartate receptor subunit mRNA in the human brain: mesencephalic dopaminergic neurons.
1998,
Pubmed
Cull-Candy,
NMDA receptor subunits: diversity, development and disease.
2001,
Pubmed
Dingledine,
The glutamate receptor ion channels.
1999,
Pubmed
Donevan,
Conantokin G is an NR2B-selective competitive antagonist of N-methyl-D-aspartate receptors.
2000,
Pubmed
,
Xenbase
Estrada,
Spider venoms: a rich source of acylpolyamines and peptides as new leads for CNS drugs.
2007,
Pubmed
Forrest,
Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death.
1994,
Pubmed
Gowd,
Conantokin-P, an unusual conantokin with a long disulfide loop.
2008,
Pubmed
Green,
Oxidative folding of conotoxins in immobilized systems.
2006,
Pubmed
Haack,
Conantokin-T. A gamma-carboxyglutamate containing peptide with N-methyl-d-aspartate antagonist activity.
1990,
Pubmed
Hammerland,
Conantokin-G selectively inhibits N-methyl-D-aspartate-induced currents in Xenopus oocytes injected with mouse brain mRNA.
1992,
Pubmed
,
Xenbase
Hollmann,
Cloned glutamate receptors.
1994,
Pubmed
Jimenez,
Conantokin-L, a new NMDA receptor antagonist: determinants for anticonvulsant potency.
2002,
Pubmed
Jones,
Protein secondary structure prediction based on position-specific scoring matrices.
1999,
Pubmed
Kabsch,
Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features.
1983,
Pubmed
Klein,
The amino acid residue at sequence position 5 in the conantokin peptides partially governs subunit-selective antagonism of recombinant N-methyl-D-aspartate receptors.
2001,
Pubmed
Küppenbender,
Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum.
2000,
Pubmed
Laurie,
Regional, developmental and interspecies expression of the four NMDAR2 subunits, examined using monoclonal antibodies.
1997,
Pubmed
Layer,
Conantokins: peptide antagonists of NMDA receptors.
2004,
Pubmed
McGuffin,
The PSIPRED protein structure prediction server.
2000,
Pubmed
McIntosh,
Gamma-carboxyglutamate in a neuroactive toxin.
1984,
Pubmed
Meldrum,
The role of glutamate in epilepsy and other CNS disorders.
1994,
Pubmed
Mena,
Conantokin-G: a novel peptide antagonist to the N-methyl-D-aspartic acid (NMDA) receptor.
1990,
Pubmed
Micu,
NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia.
2006,
Pubmed
Monyer,
Developmental and regional expression in the rat brain and functional properties of four NMDA receptors.
1994,
Pubmed
Olivera,
Subtype-selective conopeptides targeted to nicotinic receptors: Concerted discovery and biomedical applications.
2008,
Pubmed
Olivera,
Diversity of the neurotoxic Conus peptides: a model for concerted pharmacological discovery.
2007,
Pubmed
Ozawa,
Glutamate receptors in the mammalian central nervous system.
1998,
Pubmed
Prorok,
Calcium binding properties of synthetic gamma-carboxyglutamic acid-containing marine cone snail "sleeper" peptides, conantokin-G and conantokin-T.
1996,
Pubmed
Rigby,
Role of gamma-carboxyglutamic acid in the calcium-induced structural transition of conantokin G, a conotoxin from the marine snail Conus geographus.
1997,
Pubmed
Schüler,
Formation of NR1/NR2 and NR1/NR3 heterodimers constitutes the initial step in N-methyl-D-aspartate receptor assembly.
2008,
Pubmed
,
Xenbase
Sheng,
Subtype-selective antagonism of N-methyl-D-aspartate receptor ion channels by synthetic conantokin peptides.
2007,
Pubmed
Simeone,
Molecular biology and ontogeny of glutamate receptors in the mammalian central nervous system.
2004,
Pubmed
Skjaerbaek,
Determination of the solution structures of conantokin-G and conantokin-T by CD and NMR spectroscopy.
1997,
Pubmed
Teichert,
Novel conantokins from Conus parius venom are specific antagonists of N-methyl-D-aspartate receptors.
2007,
Pubmed
Thompson,
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.
1994,
Pubmed
Ułas,
Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study.
1994,
Pubmed
Warder,
Amino acid determinants for NMDA receptor inhibition by conantokin-T.
2001,
Pubmed
White,
In vitro and in vivo characterization of conantokin-R, a selective NMDA receptor antagonist isolated from the venom of the fish-hunting snail Conus radiatus.
2000,
Pubmed
,
Xenbase
Woodward,
Constant and hypervariable regions in conotoxin propeptides.
1990,
Pubmed
